# Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis

> **NCT01424670** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 511 (actual)

## Conditions studied

- Multidrug-resistant Tuberculosis

## Interventions

- **DRUG:** Delamanid + OBR
- **DRUG:** Placebo + OBR

## Key facts

- **NCT ID:** NCT01424670
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-02
- **Primary completion:** 2016-07-04
- **Final completion:** 2016-07-04
- **Target enrollment:** 511 (ACTUAL)
- **Last updated:** 2019-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01424670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01424670, "Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01424670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*